Drugs / XZP-5955
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04996121 | Dec 2021 → Sep 2025 overdue | non-small cell lung carcinoma | Xuanzhu Biopharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XZP-5955 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04996121 ↗ |
| Route | Oral | “administered orally” NCT04996121 ↗ |